

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18


**Supplementary Data for**

**Modular chimaeric cytokine receptors with leucine zipper enhance the  
antitumor activity of CAR T cells via JAK/STAT signalling**


Matthew Bell<sup>1,2</sup>, Shannon Lange<sup>1</sup>, Besian I. Sejdiu<sup>3,8</sup>, Jorge Ibanez<sup>1</sup>, Hao Shi<sup>4</sup>, Xiang Sun<sup>4</sup>, Xiaoxi Meng<sup>4</sup>, Phuong Nguyen<sup>1</sup>, Morgan Sutton<sup>1,2</sup>, Jessica Wagner<sup>1</sup>, Anil KC<sup>4</sup>, Deanna Langfitt<sup>1</sup>, Sagar L Patil<sup>1</sup>, Haiyan Tan<sup>5</sup>, Ram Vinay Pandey<sup>6</sup>, Yuxin Li<sup>5</sup>, Zuo-Fei Yuan<sup>5</sup>, Alejandro Allo Anido<sup>1</sup>, Mitchell Ho<sup>10</sup>, Heather Sheppard<sup>7</sup>, Peter Vogel<sup>7</sup>, Jiyang Yu<sup>6</sup>, Junmin Peng<sup>5,8,9</sup>, Hongbo Chi<sup>4</sup>, M. Madan Babu<sup>3,8</sup>, Giedre Krenciute<sup>1</sup>, Stephen Gottschalk<sup>1</sup>

<sup>1</sup>Department of Bone Marrow Transplantation and Cellular Therapy, <sup>2</sup>Graduate School of Biomedical Sciences, <sup>3</sup>Center of Excellence for Data Driven Discovery, <sup>4</sup>Department of Immunology, <sup>5</sup>Center for Proteomics and Metabolomics, <sup>6</sup>Department of Computational Biology, <sup>7</sup>Department of Pathology, <sup>8</sup>Department of Structural Biology, <sup>9</sup>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>10</sup>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA






a




b







21 **Supplementary Data Figure 1: Representative flow cytometry plots.**  
22 (a) Representative flow cytometry plots for primary T cell transduction (corresponding to Figure  
23 1c). (b) Transduction and pSTAT5 expression with double transduction of IL-2R $\beta$ (2x) and  
24 IL-2R $\gamma$ (2x).



27 **Supplementary Data Figure 2: SNAP/CLIP tag confocal microscopy of Zip2R(1x).**  
28 (a) Representative images of Zip2R(1x) with endosomal markers. Scale bar = 10 $\mu$ m. (b-e)  
29 Representative images of Zip2R(1x) colocalization with (b) cell membrane, (c) Lamp1, (d) Rab11,  
30 or (e) Rab5.




33 **Supplementary Data Figure 3: STAT5 induction and cell proliferation of ZipRs**  
34 (a) pSTAT5 expression in NT, Zip2R(2x), and Zip7R(2x) T cells. (b) Representative histograms  
35 of unstimulated, IL-2, or IL-15 stimulated samples. (c) Quantification of pSTAT5 expression in  
36 unstimulated, IL-2, or IL-15 stimulated samples (N=3 biological replicates, \*p<0.05, \*\*p<0.01, one-  
37 way ANOVA with Tukey's multiple comparisons test). (d) Representative histograms of cell  
38 proliferation dye (CTV-eFluor 450) labelled NT, Zip2R(2x), or Zip7R(2x) T cells at day 3 or 10. (e)  
39 Quantification of divided and undivided cells at day 3 and day 10 (N=3 biological replicates).





41 **Supplementary Data Figure 4: Phosphoproteomics experimental workflow and sample**  
42 **quality.**


43 (a) Phosphoproteomics sample preparation workflow. (b) Dataset characteristics. (c) Pearson  
44 correlation analysis of biological replicates. (d,e) Principal component analysis of top 700 DE  
45 proteins of CD4<sup>+</sup> (d) and CD8<sup>+</sup> (e) T cells.



47

48 **Supplementary Data Figure 5: Phenotypic analysis of CAR.ZipR T cells.**


49 (a) CD4:CD8 ratio of CAR.Zip2R T cells with indicated constructs (N=3-4, mean  $\pm$  SD). (b)  
 50 Immunophenotype of CD4<sup>+</sup> (left) or CD8<sup>+</sup> (right) CAR.Zip2R T cells with indicated constructs (T<sub>N</sub>-  
 51 Like : CCR7<sup>+</sup> CD45RA<sup>+</sup>, T<sub>EM</sub> : CCR7<sup>-</sup> CD45RA<sup>-</sup>, T<sub>CM</sub> : CCR7<sup>+</sup> CD45RA<sup>-</sup>, T<sub>EMRA</sub> : CCR7<sup>-</sup> CD45RA<sup>+</sup>,  
 52 N=3-4, mean $\pm$ SD). (c) CD4:CD8 ratio of CAR.Zip7R T cells with indicated constructs (N=3-4,  
 53 mean  $\pm$  SD). (d) Immunophenotype of CD4<sup>+</sup> (left) or CD8<sup>+</sup> (right) CAR.Zip7R T cells with indicated  
 54 constructs (N=3-4, mean $\pm$ SD).



55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Supplementary Data Figure 6: Antigen sensitivity of CAR.ZipR T cells**





(a) Percentage of CD107a positive cells after 4-hour stimulation with indicated concentration of plate-bound recombinant human B7-H3 (rhB7-H3) (N=3 biological replicates, mean  $\pm$  SD). (b) Concentration of IFN $\gamma$  in cell culture supernatant after 24-hour stimulation with rhB7-H3 (N=3 biological replicates, mean  $\pm$  SD).




66  
67  
68  
69  
70  
71  
72  
73  
74

**Supplementary Data Figure 7: Repetitive cytokine production of B7-H3-CAR and B7-H3-CAR.Zip2R T cells**



Quantification of (a) B7-H3-CAR or (b) B7-H3-CAR.Zip2R T cell cytokine production following 1, 2, or 3 stimulations with A549 WT cells (N=2 biological replicates). One (#) or two (##) cytokine concentrations were greater than the limit of detection (LOD) and the LOD was plotted (IFN $\gamma$ : 50,000 pg/mL; GM-CSF: 10,000 pg/mL).



76 **Supplementary Data Figure 8: Zip2R improves GPC2.CD28z and GPC2.41BBz CAR T cell**  
77 **antitumor activity**  
78 **(a)** Transduction efficiency of GPC2 CAR and Zip2R (N=2-3 biological replicates). **(b)** 7-day  
79 repeat stimulation assay with GPC2.CD28z CAR T cells and LAN1 tumor cells at 2:1 E:T. **(c)** 7-  
80 day repeat stimulation assay with GPC2.41BBz CAR T cells and LAN1 tumor cells at 2:1 E:T. **(d)**  
81 Stimulations of tumor cell killing in 7-day repeat stimulation assay with LAN1 WT cells and CAR T  
82 cells at 2:1 E:T ratio (N=3 biological replicates, mean±SD, \*\*\*p<0.001, ns = non-significant, one-  
83 way ANOVA).




84  
 85 **Supplementary Data Figure 9: Representative bioluminescence images of mice from Fig.**  
 86 **4b.** See Figure legend 4a,b for details.



87  
 88 **Extended Data Figure 10: Zip2R augments the antitumor activity of B7-H3-CAR.Zip2R T**  
 89 **cells in the A549 model.**


90 Same experimental scheme as described in Figure 4a. Mice received a single i.v. dose of  $3 \times 10^5$   
 91 CAR T cells on day 7 post A549.GFP.ffLuc cell injection. Data for a 3<sup>rd</sup> donor (N=4-5).

92 (a) Tumor burden in the lungs as determined by serial bioluminescence imaging. (b)  
 93 Quantification of tumor flux in the lungs of treated mice (mean $\pm$ SD, \* $p < 0.05$ , \*\*\* $p < 0.001$ ,  
 94 \*\*\*\* $p < 0.0001$ , two-way ANOVA of log transformed BLI data).



95  
 96 **Supplementary Data Figure 11: Representative IHC images of lungs from untreated or**  
 97 **CAR.Zip7R T cell treated mice.**  
 98 Immunohistochemistry (IHC) of lungs from mice from the indicated treatment groups. Untreated  
 99 mice were analyzed on day 28 post tumor injection. CAR.Zip7R T cell treated mice were analyzed  
 100 on day 26 post tumor injection (day 19 post T cell injection). Hematoxylin and eosin (H&E)  
 101 staining, anti-CD3, and anti-B7-H3 staining is shown. Representative images. Top panel for  
 102 untreated and CAR.Zip7R T cells: (4x); scale bar: 1 mm. Bottom panel for untreated and  
 103 CAR.Zip7R T cells: (40x); scale bar: 100  $\mu$ m.






104  
105  
106  
107  
108  
109  
110


**Supplementary Data Figure 12: CAR.Zip2R expansion *in vivo*.**

Same experimental scheme as described in Figure 4a. Mice received a single i.v. dose of 1x10<sup>6</sup> ffLuc-expressing CAR T cells on day 7 post A549 cell injection.


(a) BLI of CAR.ffLuc and CAR.Zip2R.ffLuc T cells in A549 WT tumor bearing mice. (b) Area under the curve (AUC) of flux from day 0-20.



111  
 112 **Supplementary Data Figure 13: Marker gene expression corresponding to Fig. 4e,f**  
 113 Expression of marker genes defining CD8 exhaustion-like, CD8 effector-like, and CD8 memory-  
 114 like CAR T cells.



115  
 116 **Supplementary Data Figure 14: DEGs from CD8<sup>+</sup> or CD4<sup>+</sup> CAR.ZipR T cells.**  
 117 Corresponding to Figure 6. Global differentially expressed genes in unstimulated and stimulated  
 118 CD8<sup>+</sup> and CD4<sup>+</sup> CAR T cells.



119

120

**Supplementary Data Figure 15: Example gating strategy.**

121

Left panel: Live cell gate FSC vs SSC. Middle panel: Doublets were excluded using FSC-H vs

122

FSC-A as cells displaying double the signal of singlets. Right panel: Gates were based on non-

123

transduced T cells to account for any background binding.

124

125

126

**Supplementary Data Figure 16: Phosphoproteome dataset.** See separate Excel

127

spreadsheet.

128

129

130

131

132

**Supplementary Data Figure 17: ZipReceptor sequences.** See separate Word document.